AbbVie Inc.’s Allergan and its Korean partner Medytox Inc. won the first round of a U.S. trade dispute in which they are trying to block imports of Evolus Inc.’s Jeuveau, a rival to the Botox wrinkle treatment.

A U.S. trade judge investigating claims that Jeuveau was developed using stolen trade secrets found against Evolus and its partner, Daewoong Pharmaceutical Co., and has recommended a 10-year ban on Jeuveau imports, the companies said in statements.

Read the full article at